SS Innovations International, Inc. filed a Current Report on Form 8-K dated October 5, 2026, to furnish an updated Company Presentation for the month of October 2026. The filing, submitted under the ticker symbol SSII on the Nasdaq Stock Market, serves as a corporate update intended for shareholders and the investment community.
The presentation outlines the company’s vision to deploy technologically advanced, cost-effective surgical robotic systems to improve affordability and accessibility for patients globally. Key details regarding the company’s operational footprint include a headquarters in Gurugram, India, and a company domicile in Florida, USA. As of June 30, 2026, the company reported 486 employees.
The company highlights its proprietary SSi Mantra 3 surgical robotic system, which includes a surgical command center, patient-side robotic arm carts, and a vision cart. The system utilizes a suite of instruments branded SSi Mudra, designed for various surgical procedures including cardiac and pediatric surgery. The presentation notes that the SSi Mantra installed base currently spans 12 countries.
According to the data provided in the filing, as of September 28, 2026, the company has performed 14,503 multi-specialty surgeries. The installed base consists of 244 SSi Mantra systems across 218 hospitals, supporting 188 validated surgical procedures across 9 specialties. Notably, the company reported 755 robotic cardiac surgeries and 195 telesurgeries, with zero significant safety events reported.
The document provides a financial snapshot as of October 1, 2026, showing approximately 200 million shares outstanding. At that time, the market capitalization was approximately $0.6 billion, with a recent share price of $2.75. The company reported revenue growth of 113% in 2023 and 169% in 2024, with a compound annual growth rate (CAGR) of 66% over the period.
The company emphasizes its leadership team, including Founder and Chairman Sudhir Srivastava, who owns approximately 54% of the shares outstanding. The board includes Frederic Moll, a co-founder of Intuitive Surgical, and Vishwajyoti Srivastava, the CEO of APAC and Board Member.
The presentation discusses the global addressable market for surgical robotics, noting that over 90% of installed robotic systems are located in the US, EU, and Japan. It highlights the opportunity to address access in the rest of the world, including India, where the company has installed 225 systems. The company states that the SSi Mantra is currently under FDA review for the US market.
